Search Results - "de Bono, J.S"

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) by Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J.S., Massard, C.

“…Androgen receptor (AR) signalling remains critically important in metastatic castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III…”
Get full text

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone by Bianchini, D, Lorente, D, Rodriguez-Vida, A, Omlin, A, Pezaro, C, Ferraldeschi, R, Zivi, A, Attard, G, Chowdhury, S, de Bono, J.S

“…Abstract Background The new generation anti-androgen enzalutamide and the potent CYP17 inhibitor abiraterone have both demonstrated survival benefits in…”
Get full text

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer by Tolcher, A.W., Quinn, D.I., Ferrari, A., Ahmann, F., Giaccone, G., Drake, T., Keating, A., de Bono, J.S.

“…YM155, a small-molecule survivin suppressor, showed modest single-agent activity in a phase I study of heavily pretreated patients. This study was conducted to…”
Get full text

Molecular alterations and emerging targets in castration resistant prostate cancer by Lorente, D, De Bono, J.S

“…Abstract Prostate cancer is the most common malignancy in Western Europe, of which approximately 10–20% presents with advanced or metastatic disease. Initial…”
Get full text

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer by Fizazi, K, De Bono, J.S, Flechon, A, Heidenreich, A, Voog, E, Davis, N.B, Qi, Ming, Bandekar, R, Vermeulen, J.T, Cornfeld, M, Hudes, G.R

“…Abstract Purpose This open-label phase II trial assessed mitoxantrone/prednisone (M/P) with and without siltuximab (CNTO 328), an anti-interleukin-6 chimeric…”
Get full text

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) by Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., Dearnaley, D., Parker, C., de Bono, J. S.

“…Background: Histone deacetylase blockade can promote heat shock protein 90 (HSP90) acetylation, abrogating androgen receptor signaling. A phase II trial of the…”
Get full text

384 INVITED Targeting of PI3K/AKT and MEK Signaling by de Bono, J.S

Get full text

20 Improving outcome from advanced prostate cancer through rational drug development by de Bono, J.S

Get full text

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines by Puglisi, M, Thavasu, P, Stewart, A, de Bono, J.S, O’Brien, M.E.R, Popat, S, Bhosle, J, Banerji, U

“…Highlights • Combined EGFR and AKT inhibition was studied in NSCLC cells using gefitinib with either AKTi-1/2 or AZD5363. • A synergistic effect on cell growth…”
Get full text

Patient-Level DNA Damage and Repair Pathway Profiles Are Prognostic After Prostatectomy for High-Risk Prostate Cancer by Evans, J.R, Zhao, S.G, Tomlins, S.A, Knudsen, K.E, de Bono, J.S, Rubin, M.A, Klein, E.A, Den, R.B, Dicker, A.P, Karnes, J.R, Davicioni, E, Feng, F.Y

Get full text

2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC) by Lorente, D, Ravi, P, Mehra, N, Gillman, A, Omlin, A, Pezaro, C, Miranda, M, Mateo, J, Rescigno, P, Kolinsky, M, Porta, N, Jayaram, A, Bianchini, D, Hall, E, Ijzerman, M.J, De Bono, J.S

Get full text

Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer by Pezaro, C, Omlin, A, Perez-Lopez, R, Mukherji, D, Attard, G, Bianchini, D, Lorente, D, Parker, C, Dearnaley, D, de Bono, J.S, Sohaib, A, Tunariu, N

“…Aim To test the hypothesis that computed tomography (CT)-based signs might precede symptomatic malignant spinal cord compression (MSCC) in men with metastatic…”
Get full text

Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients With Newly–Diagnosed Non-Metastatic Prostate Cancer: Data From >690 Patients in the Control Arm of the STAMPEDE Trial by James, N.D, Spears, M.R, Clarke, N.W, Sydes, M.R, Parker, C.C, Dearnaley, D.P, Russell, J.M, Ritchie, A.W.S, Thalmann, G, De Bono, J.S, Attard, G, Amos, C, Parmar, M.K, Mason, M.D

Get full text

KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC) by McDermott, R., Graff, J.N., Antonarakis, E.S., Hoimes, C.J., Tagawa, S.T., Hwang, C., Kilari, D., Tije, A.J.T., Omlin, A., Vaishampayan, U.N., Elliott, A., Wu, H., Kim, J., Schloss, C., De Bono, J.S.

Get full text

Pembrolizumab (pembro) for docetaxel-pretreated metastatic Castration-Resistant Prostate Cancer (mCRPC): Update on KEYNOTE-199, cohorts 1-3 by Piulats, J.M., Antonarakis, E.S., Gross-Goupil, M., Goh, J.C., Vaishampayan, U.N., De Wit, R., Alanko, T., Fukasawa, S., Tabata, K., Feyerabend, S., Berger, R., Wu, H., Kim, J., Schloss, C., De Bono, J.S.

Get full text

223 POSTER Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation by LoRusso, P, Sarker, D, Von Hoff, D, Tibes, R, Derynck, M.K, Ware, J.A, Yan, Y, Demetri, G.D, de Bono, J.S, Wagner, A.J

Get full text

352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients by Sandhu, S.K, Wilding, G, Schelman, W.R, Omlin, A, Kreischer, N, Carpenter, C, Iannone, R, Kaye, S, de-Bono, J.S, Wenham, R.M

Get full text

Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial by Parker, C.C, Sydes, M.R, Mason, M.D, Clarke, N.W, Aebersold, D, de Bono, J.S, Dearnaley, D.P, Ritchie, A.W.S, Russell, J.M, Thalmann, G, Parmar, M.K.B, James, N.D

Get full text

31 Evaluating the antitumour activity of docetaxel following treatment with abiraterone acetate and steroids: Evidence for cross-resistance by Mezynski, J, Attard, G, Zivi, A, Bianchini, D, Sandhu, S, Cassidy, A. Mulick, Thompson, E, Reid, A, Baikady, B, de Bono, J.S

Get full text

1258 POSTER Phase I Clinical Trial of a Genetically Modified Oncolytic Vaccinia Virus GL-ONC1 With Green Fluorescent Protein Imaging by Biondo, A, Pedersen, J.V, Karapanagiotou, E.M, Tunariu, N, Mansfield, D, Sassi, S, Corral, J, Yap, T.A, de Bono, J.S, Harrington, K.J

Get full text